Context Therapeutics (CNTX) announced the appointment of Dr. Karen Chagin, M.D. as Chief Medical Officer, CMO, effective June 9, 2025. Dr. Chagin succeeds Dr. Karen Smith, M.D., Ph.D., MBA, LLM, who has been serving as interim CMO and will remain a member of the Company’s Board of Directors.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTX:
- Promising Progress in Context Therapeutics’ Cancer Treatment Advances: Buy Rating Affirmed
- Optimistic Buy Rating on Context Therapeutics Amid Promising Program Developments and Undervaluation
- Context Therapeutics CMO Claudio Dansky Ullmann to depart
- Innovative Bispecific Antibody CT-95 Drives Buy Rating for Context Therapeutics
- Context Therapeutics presents preclinical data on CT-95